Mylan (company)
| Mylan NV
|
|
|---|---|
 |
|
| legal form | Naamloze vennootschap |
| ISIN | NL0011031208 |
| founding | 1961 |
| Seat |
Amsterdam , Netherlands
|
| management |
|
| Number of employees | 35,000 |
| sales | 11.077 billion USD (2016) |
| Branch | pharmacy |
| Website | www.mylan.com |
| As of December 31, 2016 | |
Mylan is a Dutch pharmaceutical company headquartered in Amsterdam , operational headquarters in Hatfield in the UK and German headquarters in Bad Homburg . At the end of 2016, Mylan had almost 35,000 employees worldwide and achieved sales of 11.1 billion US dollars in fiscal 2016.
history
Mylan was founded in 1961 by the Serbian-born Milan Puškar (1934-2011) and the Italian-born Don Panoz (1935-2018) under the name Milan Pharmaceuticals in White Sulfur Springs (West Virginia) and renamed Mylan in 1972.
The company first gained importance in Germany in 2007 through the acquisition of the generics business of Merck KGaA , Darmstadt . Since then, Mylan has been one of the most important authorization holders for generic drugs in Germany, alongside companies such as Hexal AG , Ratiopharm , Sandoz and Stada , where the company operates on the market with various sub-companies such as Mylan Germany GmbH, Mylan dura GmbH and others.
Mid-2014 took over the business Mylan specialty and branded generic products for markets outside the United States by Abbott Laboratories for 5.3 billion US dollars in shares of Mylan. In early 2015, the company relocated from Canonsburg , Pennsylvania to Amsterdam . The operational headquarters were initially relocated to Potters Bar and later to Hatfield .
The company's shares are listed on NASDAQ and are part of the S&P 500 stock index .
Beginning of April 2015 announced that Mylan that its Irish competitor Perrigo for 28.9 billion US dollars would take over. On April 24, 2015, Mylan increased its offer to $ 31.27 billion, which Perrigo again rejected as being too low. On April 29, 2015, Mylan increased its offering again to $ 33 billion with a higher cash portion.
On April 21, 2015, the Israeli generics company announced Teva Pharmaceutical Industries that he Mylan for 40.1 billion US dollars (equivalent to 82 dollars per share) in a hostile takeover would take over. Around 50 percent of the purchase price was to be paid in cash and the rest in Teva shares. The prerequisite for the offer, however, is the failure of the takeover of Perrigo by Mylan. In July 2015, Teva ended its acquisition plans after Mylan successfully cracked down on it with a poison pill .
On July 20, 2016, the EU Commission approved the takeover of the Swedish MEDA group (including its subsidiaries, including Rottapharm Madaus ) by Mylan.
In September 2016, CEO Heather Bresch had to appear before representatives of the US Congress to justify the company's pricing policy for pre-filled adrenaline syringes (EpiPens) in the US. The drug was purchased by Mylan in 2007 and the retail price for a twin pack had since increased from $ 100 to $ 600.
Web links
Individual evidence
- ↑ a b c Mylan: Annual Report 2016. (PDF) Retrieved on March 2, 2017 (English).
- ↑ a b Summary of MYLAN INC. - Yahoo! Finance . In: yahoo.com .
- ↑ Contact | Mylan. Retrieved November 15, 2019 .
- ↑ WVMetroNews: Mylan Pharmaceuticals co-founder Don Panoz dies at 83 September 11, 2018, accessed November 15, 2019 (American English).
- ↑ New billion-dollar deal - Stada competitor Mylan casts an eye on Irish Perrigo ( Memento from April 19, 2015 in the Internet Archive )
- ↑ Reuters: Pharmaceutical industry in takeover fever: Teva wants Mylan, Mylan wants Perrigo . In: handelsblatt.com . April 24, 2015.
- ↑ FOCUS Online: Company: Pharmaceutical company Mylan wants to move Perrigo with more cash to take over . In: FOCUS Online . April 29, 2015.
- ↑ Jonathan D. Rockoff And Dana Mattioli: Teva Offers to Buy Mylan for $ 40 Billion . In: WSJ . April 22, 2015.
- ↑ Teva Makes $ 40 Billion Unsolicited Takeover Bid for Mylan . In: Bloomberg.com . April 21, 2015.
- ↑ Teva Proposes to Acquire Mylan for $ 82.00 Per Share in Cash and Stock . In: businesswire.com . April 21, 2015.
- ↑ Reuters: Takeover offer: Perrigo rejects Mylan's offer . In: handelsblatt.com . April 21, 2015.
- ↑ Teva Snaps Up Allergan's Generics Arm, Dumping Mylan . In: Bloomberg.com . July 27, 2015.
- ↑ Carolyn Y. Johnson, "Lawmakers grill Mylan CEO over EpiPen price hikes," Washington Post, September 22, 2016